Syngene International Limited is a leading global contract research organization (CRO) that offers integrated drug discovery and development services. Established in 1993, Syngene provides scientific expertise, state-of-the-art infrastructure, and flexible business models to support its clients in accelerating the discovery and development of novel therapeutics.

The company's comprehensive suite of services includes medicinal chemistry, biology, toxicology, process R&D, formulation development, analytical development, and cGMP manufacturing. Syngene caters to an extensive range of global pharmaceutical and biotechnology companies across various therapeutic areas such as oncology, immunology & inflammation, metabolic disorders & complications associated with diabetes mellitus.

One of the key factors that sets Syngene apart from its competitors is its focus on innovation. The company consistently invests in cutting-edge technologies to enhance efficiency and productivity in drug discovery processes. For instance,Syngene’s technology platforms encompass advanced capabilities like structural biology (X-ray crystallography), genomics solutions using next-generation sequencing (NGS), virtual screening software for computational drug design among others.

Besides its internal advancements through robust research facilities at Biocon Park - Bengaluru; the company has also entered into strategic partnerships with industry leaders including Amgen Inc., Baxter Healthcare Corporation along with collaborations with academic institutions fostering innovative research while expanding their service offerings.

In addition to delivering high-quality science-based solutions tailored to meet specific client needs effectively; Syngene's commitment towards sustainability by implementing green initiatives has garnered significant attention within CRO sector.